Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), today announced a collaboration with Kodiak Sciences Inc This partnership aims to advance the discovery of novel multi-target antibodies

Woolsey Pharmaceuticals, a clinical-stage pharmaceutical company developing BRAVYL (oral fasudil) for the treatment of Amyotrophic Lateral Sclerosis (ALS), announced that a poster by Dr. Daniel Linseman's laboratory at the University

Genmab A/S today announced results from the Phase 1b/2 EPCORE® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated

Seres Therapeutics, Inc. a leading live biotherapeutics company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SER-155, the Company’s lead investigational program

AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC).

Muna Therapeutics a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced a research alliance with GSK to identify and validate novel drug targets for the treatment

Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly’s biotech collaborators.

Nxera Pharma Co., Ltd – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the first patient in a Phase 3 clinical trial evaluating daridorexant, its novel dual orexin receptor antagonist

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Clearway Health, a specialty pharmacy services company partnering with hospitals and health systems to build and strengthen specialty pharmacy.